Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P455 Adherence to enteral nutrition therapy by adults with active Crohn’s disease is associated with conscientiousness personality trait

ECCO'20 Vienna

Year: 2020
Authors:

C. Wall1, A. McCombie2, R. Mulder3, A. Day4, R. Gearry1

1Department of Medicine, University of Otago, Christchurch, New Zealand, 2Department of General Surgery, Canterbury District Health Board, Christchurch, New Zealand, 3Department of Psychological Medicine, University of Otago, Christchurch, New Zealand, 4Department of Paediatrics, University of Otago, Christchurch, New Zealand

P456 Longer-term outcomes in acute severe colitis

ECCO'20 Vienna

Year: 2020
Authors:

R. CAMPBELL, R. Haddock, K. Parman, J. MacDonald, J.P. Seenan

Gastroenterology, Queen Elizabeth University Hospital, Glasgow, UK

P457 IBD couples and their offspring: a European survey

ECCO'20 Vienna

Year: 2020
Authors:

A. Oliveira1, M.P. Costa-Santos1, C. Frias Gomes1, J. Sabino2, A. Sampaio3, L. Avedano4, S. Leone4, J.F. Colombel5, J. Torres1

1Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal, 2Gastroenterology, University Hospital of Leuven, Leuven, Belgium, 3Portuguese Association of Inflammatory Bowel Disease, Portuguese Association of Inflammatory Bowel Disease, Lisbon, Portugal, 4European Federation of Crohn’s and Ulcerative Colitis Associations EFCCA, European Federation of Crohn’s and Ulcerative Colitis Associations EFCCA, Brussels, Belgium, 5Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, USA

P458 Association between adalimumab serum levels and level of remission in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

S. Hambli1, S. Rogeau2, N. Duveau3, M. Nachury1, J. Branche1, R. Gérard1, P. Wils1, C. Lauriot Dit Prevost1, T. Lambin1, P. Desreumaux1, M. Labalette2, B. Pariente1

1CHRU Lille, Service des Maladies de l’Appareil Digestif et Nutrition, Lille, France, 2CHRU Lille, Institut d’immunologie, Lille, France, 3Service d’Hépato-Gastro-entérologie, Centre Hospitalier de Roubaix, Roubaix, France

P459 The impact of latent cytomegalovirus infection on the disease behaviour in patients with ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

P. Långvall1, C. Shi1, P. Karling2

1Department of Public Health and Clinical Medicine- Umeå University, Medicine, Umeå, Sweden, 2Department of Public Health and Clinical Medicine- Umeå University, Norrlands University Hospital NUS Umeå, Umeå, Sweden

P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis

ECCO'20 Vienna

Year: 2020
Authors:

A. Clarke, J. Di Paolo, B. Downie, A. Meng, N. Mollova, Y. Yu, P. Han

Clinical Development, Gilead Sciences Inc., Foster City- CA, USA

P461 Intolerance to 5-aminosalicylate is a risk of poor prognosis in ulcerative colitis patients

ECCO'20 Vienna

Year: 2020
Authors:

T. Fujii1, S. Hibiya1, C. Maeyashiki2, E. Saito1, K. Takenaka1, M. Motobayashi1, H. Shimizu1, M. Nagahori1, K. Ohtsuka1, M. Kurosaki2, T. Yauchi3, M. Watanabe1

1Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan, 2Gastroenterology, Musashino Red Cross Hospital, Tokyo, Japan, 3Gastroenterology, Soka Municipal Hospital, Soka, Japan

P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry

ECCO'20 Vienna

Year: 2020
Authors:

M. Mañosa Ciria1, A. Fernandez-Clotet2, A. Hernández-Camba3, R. Muñoz Pérez4, M. Iborra5, M. Sierra6, L. Márquez7, P. Delgado-Guillena8, D. Busquets9, M. Van Domselaar10, E. Girona11, E. Sánchez-Rodríguez12, M.D. Martín-Arranz13, R. Lorente14, D. Casas-Deza15, M. Boscá16, F. Cañete1, M. Calafat1, E. Domènech1

1Department of Gastroenterology CIBERehd- IBD Unit, Hospital Universitari Germans Trias I Pujol, Badalona, Spain, 2Gastroenterology, Hospital Clinic Barcelona, Barcelona, Spain, 3Gastroenterology, Hospital Nuestra Señora de la Candelaria, Tenerife, Spain, 4Gastroenterology, Hospital General Universitario de Alicante, Alicante, Spain, 5Gastroenterology, Hospital La Fe, Valencia, Spain, 6Gastroenterology, Hospital Universitario de Leon, Leon, Spain, 7Gastroenterology, Hospital del mar, Barcelona, Spain, 8Gastroenterology, Hospital General de Granollers, Granollers, Spain, 9Gastroenterology, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain, 10Gastroenterology, Hospital de Torrejon, Torrejon, Spain, 11Gastroenterology, Hospital General Universitario de Elche, Elche, Spain, 12Gastroenterology, Hospital Ramon y Cajal, Madrid, Spain, 13Gastroenterology, Hospital la Paz, Madrid, Spain, 14Gastroenterology, Hospital de Ciudad Real, Ciudad Real, Spain, 15Gastroenetrology, Hospital Miguel Servet, Zaragoza, Spain, 16, Gastroenterology, Hospital Universitario Clínico de Valencia, Valencia, Spain

P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Vickers1, A. Nag2, B. Devine3, B.E. Sands4, R. Panaccione5, L. Peyrin-Biroulet6, S. Danese7, S. Vermeire8, K.J. Gorelick9, M. Goetsch10, L. Hartley1

1RTI Health Solutions, Data Analytics and Design Strategy, Manchester, UK, 2Shire- a Takeda company, Health Economics- Outcomes Research and Epidemiology, Lexington, USA, 3School of Pharmacy, University of Washington, Seattle, USA, 4Icahn School of Medicine at Mount Sinai Medical Center, Dr Henry D. Janowitz Division of Gastroenterology, New York, USA, 5Division of Gastroenterology, University of Calgary, Calgary, Canada, 6Department of Gastroenterology, University Hospital of Nancy-Brabois, Vandœuvre-lès-Nancy, France, 7IBD Center, Humanitas University, Milan, Italy, 8Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium, 9Zymo Consulting Group, Clinical Development, Newtown Square, USA, 10Shire- a Takeda Company, Clinical Development, Zug, Switzerland

P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation

ECCO'20 Vienna

Year: 2020
Authors:

N. Van den Berghe1, B. Verstockt2,3, A. Gils1, M. Ferrante2,3, S. Vermeire2,3, D. Thomas1

1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 2Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 3Department of Chronic Diseases- Metabolism and Ageing, KU Leuven, Leuven, Belgium

P465 Therapeutic drug monitoring in Crohn’s disease patients, a comparison between homogeneous mobility shift assay and point of care method

ECCO'20 Vienna

Year: 2020
Authors:

G. Bodini1, M.G. Demarzo1, A. Djahandideh1, I. Baldissarro1, E. Savarino2, V. Savarino3, A. Jain4, P.M. Risso3, E.G. Giannini3

1Gastroenterology Unit- Department of Internal Medicine, University of Genoa, Genoa, Italy, 2Department of Surgery- Oncology and Gastroenterology, University of Padua, Padua, Italy, 3Department of Internal Medicine, University of Genoa, Genoa, Italy, 4Department of Research and Development, Prometheus Laboratories Inc., San Diego, USA

P466 Is it possible avoid colectomy with rescue dual therapy with vedolizumab plus tacrolimus in ulcerative colitis that losing response to anti-tumour necrosis factor?

ECCO'20 Vienna

Year: 2020
Authors:

L. Sanchis1, J.R. Molés1, J. Borrás2, J. Rodriguez1, X. Cortés1

1Department of Digestive Disease, Hospital of Sagunto, Sagunto, Spain, 2Department of Pharmacology, Hospital of Sagunto, Sagunto, Spain

P467 Can induction and maintenance serum vedolizumab levels predict long-term clinical outcome in inflammatory bowel disease (IBD)?

ECCO'20 Vienna

Year: 2020
Authors:

C. Miller1, H. Morgan2, A. Steel3, M. Wahed4

1Chelsea and Westminister Hospital Department of Gastroenterology, 1Gastroenterology, University College Hospital, London, UK, 2Gastroenterology, Chelsea and Westminister Hospital, London, UK, 3Gastroenterology, The Royal Liverpool University and Broadgreen University Hospitals NHS Trust, Liverpool, UK, 4Gastroenterology, Cheslsea and Westminister Hospital, London, UK

P468 Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study

ECCO'20 Vienna

Year: 2020
Authors:

B. Barberio1, P. Melatti1, F. Zingone1, L. Bertani2, A. Ferronato3, A. GUBBIOTTI1, D. Massimi4, R. D’Incà1, E.V. Savarino5

1Department of Surgery Oncology Gastroenterology, University of Padua, Padua, Italy, 2Department of Gastroenterology, University of Padua, Pisa, Italy, 3Gastroenterology Unit, Santorso Hospital, Santorso, Italy, 4Department of Surgery- Oncology- Gastroenterology, Univeristy of Padua, Padua, Italy, 5Department of Surgery- Oncology- Gastroenterology, University of Padua, Padua, Italy

P469 Stay in class or switch out of class after anti-TNF failure in inflammatory bowel disease (IBD). Real-world data from a large district general hospital

ECCO'20 Vienna

Year: 2020
Authors:

H. Johnson, S. Vythilingam, S. McLaughlin

Department of Gastroenterology, Royal Bournemouth Hospital, Bournemouth, UK

P470 The concept of illness identity in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

L.L. Knödler1, A. Thomann2, M.P. Ebert2, S. Lis3, W. Reindl2

1Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, 2Department of Medicine II, Medical Faculty Mannheim- Heidelberg University, Mannheim, Germany, 3Institute of Psychiatric and Psychosomatic Psychotherapy- Central Institute of Mental Health, Medical Faculty Mannheim- Heidelberg University-, Mannheim, Germany

P471 What is the appropriate cut-off value of CRP to predict endoscopic remission in ulcerative colitis patients with clinical remission?

ECCO'20 Vienna

Year: 2020
Authors:

J. Shin, G. Seong, J.H. Song, S.M. Kong, T.J. Kim, E.R. Kim, S.N. Hong, D.K. Chang, Y.H. Kim

Samsung Medical Center, Internal Medicine Gastroenterology and Hepatology, Seoul, Republic of Korea

P472 Optimising the development of apps for the management of inflammatory bowel disease and participation in clinical trials

ECCO'20 Vienna

Year: 2020
Authors:

F. Hussain1, M. DeLegge2, M. Copeman3, M.B. Gallagher2, T. Stewart2, G. Georgiev4

1Iqvia, Therapeutic Science and Strategy Unit, Reading, UK, 2Iqvia, Therapeutic Science and Strategy Unit, Raleigh, USA, 3Iqvia, Project Leadership, Reading, UK, 4Iqvia Bulgaria, Therapeutic Science and Strategy Unit, Sofia, Bulgaria

P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD

ECCO'20 Vienna

Year: 2020
Authors:

C. Padilla Suarez, K. Webb, N. Persad, J. Sercombe, E. Tyler, K. Klimova

Gastroenterology, University Hospitals Plymouth NHS Trust, Plymouth, UK

P474 Efficacy and safety of GCAP therapy for UC with PSC

ECCO'20 Vienna

Year: 2020
Authors:

A. Ito, S. Murasugi, T. Omori, M. Yonezawa, K. Tokushige

Department of Gastroenterology- Department of Medicine, Tokyo Women’s Medical University Hospital, Tokyo, Japan